商湯(00020.HK)曾瀉5成創上市新低 管理層自願承諾延長股份限售期
商湯(00020.HK)今日(30日)部分上市限售股份解禁,公司管理層則宣佈自願延長股份鎖定期至今年12月29日前,惟開市後大跌15%後快速走低,股價更曾「腰斬」暴瀉5成,低見2.91元,現跌46%,最新報3.18元,失守上市價3.85元。
商湯表示,徐立、王曉剛、徐冰及若幹管理層成員自願承諾,於今年12月29日之前,不會出售公司於2016年11月1日採納的首次公開發售前受限制股份單位計劃下已歸屬的受限制股份單位所涉及的B類股份;及/或公司於2016年11月1日採納的首次公開發售前僱員激勵計劃下已歸屬的期權獲行使所涉及的B類股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.